GoGood Genetics

gogoodgenetics.com

GoGood Genetics is a biotechnology company specialized in direct genetic testing for consumers. It makes personalized studies in which it determines the interactions of nutrition with the genetic profile of each individual. In the market it has 4 genetic tests: Vital, Intolerance, Diet and Sport. Knowing someone's genes, you can know what diet is best for your health, prevent diseases and, ultimately, lead a healthier and better quality life.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMA TECH

FLAGSHIP PIONEERING AND SAMSUNG ANNOUNCE COLLABORATION TO ADVANCE GROUNDBREAKING TECHNOLOGIES IN TRANSLATIONAL SCIENCE AND MEDICINE

PR Newswire | January 09, 2024

news image

Flagship Pioneering, the bioplatform innovation company, and Samsung today announced a collaboration aimed at fostering cutting-edge biopharmaceutical innovation poised to transform the world of healthcare through groundbreaking advancements in translational science and medicine. Through this collaboration, Samsung will work alongside Flagship-founded companies, leveraging Samsung's leading technologies and capabilities to accelerate first and best-in-class therapies. The ne...

Read More

Business Insights

AQUESTIVE THERAPEUTICS RECEIVES FDA TENTATIVE APPROVAL FOR LIBERVANT™ (DIAZEPAM) BUCCAL FILM

Aquestive Therapeutics, Inc. | August 31, 2022

news image

Aquestive Therapeutics, Inc. a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today that the U.S. Food & Drug Administration has granted tentative approval for Libervant™ Buccal Film for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity that are distinct from a patient’s usual seizure pattern in patients with epileps...

Read More

Pharma Tech

HOLOGIC LAUNCHES PANTHER TRAX FOR HIGH VOLUME MOLECULAR TESTING

Hologic | December 24, 2021

news image

Hologicannounced that it has completed regulatory filings needed to make Panther Trax® available in a number of countries and regions. Launch of Panther Trax represents the latest addition to the Panther® Scalable Solutions portfolio of products, offering the ultimate in lab automation by physically linking multiple Panther instruments together into a single, powerful workcell that allows labs to increase testing volumes without increasing staff. Panther Trax is now listed...

Read More

DURHAM’S MYCOVIA PHARMA EXTENDS CLINICAL TRIAL OF ANTI-FUNGAL DRUG FOR YEAST INFECTIONS

WRAL TechWire | February 11, 2020

news image

Mycovia Pharmaceuticals, a developer of drugs in women’s health, has initiated “extension studies” as part of its ongoing Phase 3 global clinical trial of its lead drug candidate for treating recurrent yeast infections in women. The Durham-based firm is developing oteseconazole (VT-1161), an oral antifungal product candidate, for the treatment of Recurrent Vulvovaginal Candidiasis (RVVC), a debilitating, chronic infectious condition that affects nearly 138 million women worldwi...

Read More
news image

PHARMA TECH

FLAGSHIP PIONEERING AND SAMSUNG ANNOUNCE COLLABORATION TO ADVANCE GROUNDBREAKING TECHNOLOGIES IN TRANSLATIONAL SCIENCE AND MEDICINE

PR Newswire | January 09, 2024

Flagship Pioneering, the bioplatform innovation company, and Samsung today announced a collaboration aimed at fostering cutting-edge biopharmaceutical innovation poised to transform the world of healthcare through groundbreaking advancements in translational science and medicine. Through this collaboration, Samsung will work alongside Flagship-founded companies, leveraging Samsung's leading technologies and capabilities to accelerate first and best-in-class therapies. The ne...

Read More
news image

Business Insights

AQUESTIVE THERAPEUTICS RECEIVES FDA TENTATIVE APPROVAL FOR LIBERVANT™ (DIAZEPAM) BUCCAL FILM

Aquestive Therapeutics, Inc. | August 31, 2022

Aquestive Therapeutics, Inc. a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today that the U.S. Food & Drug Administration has granted tentative approval for Libervant™ Buccal Film for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity that are distinct from a patient’s usual seizure pattern in patients with epileps...

Read More
news image

Pharma Tech

HOLOGIC LAUNCHES PANTHER TRAX FOR HIGH VOLUME MOLECULAR TESTING

Hologic | December 24, 2021

Hologicannounced that it has completed regulatory filings needed to make Panther Trax® available in a number of countries and regions. Launch of Panther Trax represents the latest addition to the Panther® Scalable Solutions portfolio of products, offering the ultimate in lab automation by physically linking multiple Panther instruments together into a single, powerful workcell that allows labs to increase testing volumes without increasing staff. Panther Trax is now listed...

Read More
news image

DURHAM’S MYCOVIA PHARMA EXTENDS CLINICAL TRIAL OF ANTI-FUNGAL DRUG FOR YEAST INFECTIONS

WRAL TechWire | February 11, 2020

Mycovia Pharmaceuticals, a developer of drugs in women’s health, has initiated “extension studies” as part of its ongoing Phase 3 global clinical trial of its lead drug candidate for treating recurrent yeast infections in women. The Durham-based firm is developing oteseconazole (VT-1161), an oral antifungal product candidate, for the treatment of Recurrent Vulvovaginal Candidiasis (RVVC), a debilitating, chronic infectious condition that affects nearly 138 million women worldwi...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us